Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALIANT: Allogeneic hMSCs for Facetogenic Back Pain
NCT03487731Phase 2Withdrawn
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic human mesenchymal stem cells in Facet Joint Disorder. Planned start Dec 2020; status: withdrawn.
02
Drugs
allogeneic human mesenchymal stem cells
03
Conditions
Facet Joint Disorder
Beyond the preview
Go deeper on NCT03487731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03487731.